Growth Hormone, Insulin-Like Growth Factors, and the Skeleton
Author(s) -
Andrea Giustina,
Gherardo Mazziotti,
Ernesto Canalis
Publication year - 2008
Publication title -
endocrine reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.357
H-Index - 272
eISSN - 1945-7189
pISSN - 0163-769X
DOI - 10.1210/er.2007-0036
Subject(s) - endocrinology , medicine , acromegaly , osteoporosis , bone remodeling , osteoblast , peak bone mass , skeleton (computer programming) , pathogenesis , insulin like growth factor , homeostasis , growth factor , hormone , bone density , biology , growth hormone , receptor , anatomy , biochemistry , in vitro
GH and IGF-I are important regulators of bone homeostasis and are central to the achievement of normal longitudinal bone growth and bone mass. Although GH may act directly on skeletal cells, most of its effects are mediated by IGF-I, which is present in the systemic circulation and is synthesized by peripheral tissues. The availability of IGF-I is regulated by IGF binding proteins. IGF-I enhances the differentiated function of the osteoblast and bone formation. Adult GH deficiency causes low bone turnover osteoporosis with high risk of vertebral and nonvertebral fractures, and the low bone mass can be partially reversed by GH replacement. Acromegaly is characterized by high bone turnover, which can lead to bone loss and vertebral fractures, particularly in patients with coexistent hypogonadism. GH and IGF-I secretion are decreased in aging individuals, and abnormalities in the GH/IGF-I axis play a role in the pathogenesis of the osteoporosis of anorexia nervosa and after glucocorticoid exposure.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom